Andor Glaudemans
prof. dr.
I am a nuclear medicine specialist and always trying to implement innovative diagnostic and therapeutic methods in imaging. My main research interests involve infectious and inflammatory diseases, tumor-immunology, and development of new-targeted diagnostic tools for PET imaging. The latter focus is carried out in close collaboration with our radiochemists. Within the lymphoma research Groningen team we have a close collaboration with the department of hematology. The research is focused on finding new methods for diagnosis and therapy evaluation in several types of lymphomas. We have a special interest in post-transplant lymphatic disorders (PTLD). Furthermore, we are developing and evaluating several fields of radionuclide therapy, so called theranostics.
FDG-PET/CT for diagnosis of cyst infection in autosomal dominant polycystic kidney disease
Published in: Clinical and Translational Imaging
Access to document
10.1007/s40336-017-0261-8
document
Purpose: Cyst infections are a common complication in autosomal dominant polycystic kidney disease (ADPKD). Diagnosing these infections often remains challenging. Conventional imaging techniques such as ultrasonography, computed tomography (CT), and standard magnetic resonance imaging have several drawbacks and disadvantages. The purpose of this pictorial essay was to illustrate and discuss the potential value of18F-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET)/CT in diagnosing cyst infection in ADPKD. Methods: Exemplary (ADPKD) patients who underwent FDG-PET/CT as part of their routine clinical work-up in our institution are presented to show the potential value...
Whole body PD-L1 PET in patients with NSCLC and melanoma.
Published in: Journal of Clinical Oncology
Access to document
10.1200/jco.2018.36.5_suppl.139
Background: PD-(L)1 immunotherapy is effective in multiple tumors, including NSCLC and melanoma, but tumor PD-L1 IHC correlates only moderately with treatment outcome. This study aims to assess 1) safety of 18F-BMS-986192 (18F-PD-L1) in human, 2) PD-L1 quantification in tumors using 18F-PD-L1 PET, 3) PD-L1 PET correlation with IHC and treatment outcome, and 4) intra and inter subject tracer uptake variability.Methods: Pts with NSCLC (N = 10) and melanoma (N = 3) were included. At baseline, pts received a static or multiphase dynamic whole body PET scan after injecting...
David K. Leung, Joop De Langen, David Raunig, Anna-Larissa N. Niemeijer, Egbert F. Smit, Ronald Boellaard, David Vállez García, G.a.M.S. van Dongen, A.D. Windhorst, Marc C. Huisman, Andor W. J. M. Glaudemans, N. Harry Hendrikse, Ralph Adam Smith, Alex J. Poot, Dasa Lipovsek, David J. Donnelly, Samuel J. Bonacorsi, Linda M. Velasquez, Shuyan Du, Wendy Hayes
A joint procedural position statement on imaging in cardiac sarcoidosis: From the Cardiovascular and Inflammation & Infection Committees of the European Association of Nuclear Medicine, the European Association of Cardiovascular Imaging, and the American Society of Nuclear Cardiology
Published in: Journal of Nuclear Cardiology
Access to document
10.1007/s12350-017-1043-4
document
Riemer H. J. A. Slart, Andor W. J. M. Glaudemans, Patrizio Lancellotti, Fabien Hyafil, Ron Blankstein, Ronald G. Schwartz, Wael A. Jaber, Raymond Russell, Alessia Gimelli, Francois Rouzet, Marcus Hacker, Olivier Gheysens, Sven Plein, Edward J. Miller, Sharmila Dorbala, Erwan Donal, Document Reading Grp
Performance of advanced imaging modalities at diagnosis and treatment response evaluation of patients with post-transplant lymphoproliferative disorder: A systematic review
Filipe Montes de Jesus, Thomas Kwee, Marcel Nijland, Xaver-Ulrich Kahle, Geert Huls, Rudi Dierckx, Tom van Meerten, Olivier Gheysens, D Dierickx, Walter Noordzij, Andor W.J.M. Glaudemans
Imaging Cardiac Innervation in Hereditary Transthyretin (ATTRm) Amyloidosis: a Marker for Neuropathy or Cardiomyopathy?